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Cannabis and epilepsy 
 
Abstract 
The one-third of people who do not gain seizure control through current treatment options 
need a revolution in epilepsy therapeutics.  The general population appears to be showing a 
fundamental and rapid shift in its opinion regarding cannabis and cannabis-related drugs. It 
is quite possible that cannabidiol, licensed in the USA for treating rare genetic epilepsies, 
may open the door for the widespread legalisation of recreational cannabis. It is important 
that neurologists understand the difference between artisanal cannabidiol products 
available legally on the high street and the cannabidiol medications that have strong trial 
evidence.  In the UK in 2018 there are multiple high-profile reports of the response of 
children taking cannabis-derived medication, meaning that neurologists are commonly 
asked questions about these treatments in clinic. We address what an adult neurologist 
needs to know now, ahead of the likely licensing of Epidiolex in the UK in 2019.  
 
Introduction 
We have seen a surge in interest in the medicinal use of cannabis and cannabis extracts for 
people with epilepsy. Historically, there are reports from ancient and medieval times of 
using cannabis to treat epilepsy. During the 19th century, the introduction of medicinal 
cannabis into Western medicine was driven by the experiences and studies of William 
O’Shaughnessy, from his time working in India with the East India Company. His publications 
led to the acceptance of the use of cannabis in Victorian England. Indeed, two distinguished 
neurologists of that era, J.R. Reynolds and William Gowers, documented their experiences 
with cannabis, particularly for the treatment of epilepsy.  However, in the 20th century, 
fluctuating public morals and worries about cannabis’ psychoactive properties triggered the 
global outlawing of cannabis. 
In 2018 there have both been developments in class I evidence from randomised controlled 
trials, and a growing momentum of patient stories based on lived experiences. In June 2018 
the US Food and Drug Administration (FDA) approved Epidiolex, a cannabidiol oral solution 
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for use in Lennox–Gastaut and Dravet syndrome for patients aged 2 years and over.[1] This 
is a landmark as it represents not only the first FDA approval for a drug specifically trialled in 
Dravet syndrome but also the first drug that contains a purified substance derived from 
marijuana. 
Cannabis-derived drugs are very different from cannabis that is available legally or illegally, 
in terms of the reliability of their content and purity; and cannabis-derived medications 
differ from cannabidiol oils. The drugs are either extracted from plants—such as Epidiolex, 
the cannabidiol (CBD) is a cannabinoid prepared from the Cannabis sativa L. plant—or they 
are synthesised. CBD oils vary greatly, and commercial CBD oil sites trumpet this impurity as 
a benefit: such as the claim by ‘Charlotte’s Web’ “Counter normal, everyday stresses with 
the goodness of nature. Cannabidiol (CBD) plus other naturally occurring phytocannabinoids, 
terpenes, flavonoids and more in every serving.” 
The number of active compounds within cannabis is debated but tetrahydrocannabinol 
(THC), cannabidiol (CBD) and cannabidivarin are but three of approximately 85 known. The 
available pharmaceutical drugs are a balance between CBD and THC; the more THC that a 
drug contains, the more psychoactive it is likely to be, producing either a ‘high’ or a calming 
effect. In general, the products appear well tolerated, and gastro-intestinal side effects are 
the most prominent. However, a systematic review of cannabinoids (typically CBD plus THC) 
for pain, nausea and spasticity reported that the ‘number needed to harm’ was between 8 
and 22. Central effects were most common (dizziness, sedation confusion and dissociation), 
and 35–70% reported “feeling high”.[2] Epidiolex is 99% CBD (0.1% THC) in contrast to the 
oromucosal spray Sativex (nabiximols), which is a 50/50 mixture of the two. The FDA have 
approved two further cannabinoid drugs: Syndros or Marinol (dronabinol) to treat anorexia 
in patients with AIDS and chemotherapy-associated nausea; and Cesamet (nabilone) again 
for intractable chemotherapy nausea. Dronabinol is a gelatine capsule containing delta-9-
tetrahydrocannabinol whilst nabilone is a synthetic cannabinoid that acts like THC.  
 
The state of play 
In the UK, cannabidiol (CBD) is being studied at major paediatric neurology centres such as 
Muir Maxwell Epilepsy Centre in Edinburgh, Great Ormond Street Hospital in London, The 
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Royal Hospital for Sick Children in Glasgow and Alder Hey Children’s Hospital in Liverpool. 
Studies began in 2014 and as such there is a growing clinical experience with Epidiolex. 
Trials were initially in Dravet syndrome and some of these children may have transitioned in 
to adult neurology over time.  
Cannabidiol trials reporting over the last two years have successfully transitioned the 
position of the drug from ‘anecdotal and promising’ to ‘proven to be effective’. Well-
designed placebo-controlled trials in patient groups who are not normally recruited to 
epilepsy drug studies (children and people with intellectual disability) have established the 
benefit of Epidiolex in Dravet and Lennox–Gastaut syndromes.[3-5] The study in Dravet 
syndrome recruited 120 children and young adults, whereas the Lennox–Gastaut papers 
randomised 225 children and 171 young adults. Interesting points include the 5% of patients 
with Dravet syndrome who became seizure free (none on placebo); seizure freedom in 
Dravet syndrome is very rare. Both Lennox–Gastaut syndrome papers focussed on drop 
seizures, which are disabling and injurious. The Devinksy et al. paper [4] randomised to 
three groups, allowing comparison of 10mg and 20mg doses; both active arms saw a 
significant reduction in drop seizures compared to placebo.  
 
Australia, Argentina, Canada, Colombia, the Czech Republic, Denmark, Finland, Germany, 
Greece, Israel, Italy, the Netherlands, Poland, Switzerland, Uruguay and Zimbabwe are 
amongst the nations where medicinal cannabis-derived drugs are legal. Cannabis remains a 
Schedule I drug in most parts of the USA, despite a movement to legalise cannabis and 
cannabis-derived drugs in many states. Schedule I drugs are defined as drugs with no 
currently accepted medical use and a high potential for abuse; including heroin, LSD and 
ecstasy. Hemp-derived CBD is legal in all 50 states, whereas marijuana-CBD (more likely to 
be THC-rich) is legal for medicinal purposes in 46 states and legal for recreational purposes 
in 8 of those states without a prescription; namely Alaska, California, Colorado, Maine, 
Massachusetts, Nevada, Oregon, and Washington. In the UK, cannabis is a class B drug, 
which means that a criminal conviction for producing and supplying the drug could be 
punished with a maximum of 14 years in prison, an unlimited fine, or both. This is a 
precarious situation. If the individual wants to travel abroad with a cannabis-derived drug 
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they would need to investigate intensively the legal status of the compounds in the country 
they wish to visit; in the same way that codeine or clobazam need to be considered. 
Cannabis is a Schedule 1 drug in the UK within the Misuse of Drugs Regulations 2001 
(pertaining to lawful possession and supply)[6] but in July 2018 the Advisory Council on the 
Misuse of Drugs recommended it should be downgraded to Schedule 2, in theory allowing 
clinicians to prescribe cannabis. However, cannabidiol that is devoid of THC is classified as 
Schedule 4; Sativex, despite its THC, has special dispensation to be Schedule 4,.  
Each nation’s approach to CBD has been different. In Denmark, for example, cannabis-
derived products (including Sativex) were legalised for a four-year trial period from January 
1st 2018. This opened the door to imported products and to those manufactured outside of 
traditional pharmaceutical processes. This meant that the Danes had to cope with certain 
practical issues ahead of many other nations. Their approach to driving eligibility was to 
state that anyone taking it must respect a complete driving ban – although they 
immediately softened this stance by allowing a clinician’s discretion to be used, providing 
that there was no discernible THC in the preparation used. Also, clinicians had to learn 
quickly how best to advise and dose people who wanted their cannabis-derived products in 
non-standard ways – such as in tea-like infusions. The primary indications for cannabis-
deprived products in Denmark have been multiple sclerosis and nausea and vomiting in 
palliative care. 
There are currently 151 clinical trials listed on clinicaltrials.gov, the American (NIH) 
repository of studies, 21 of which relate to epilepsy. There are ongoing trials for cancer pain, 
schizophrenia and new epilepsy indications. A recent systematic review confirms that CBD is 
more effective than placebo at reducing seizure burden (50% seizure reduction) – with a 
relative risk of 1.7–2.4, and a number needed to treat of 8.[7] Across twelve pooled 
observational studies there was a 56% increase in quality of life, a 51% rate of adverse 
events and a 2.2% risk of serious adverse events. They noted that there was more reliance 
than usual on observational studies than randomised controlled trials; extension studies are 
less likely to feature patients who cannot tolerate the drug.  
On the 19th April 2018 the Food and Drug Administration (FDA) published a briefing 
document following a request from GW Pharmaceuticals to appraise the evidence behind 
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CBD for treating seizures in Lennox–Gastaut and Dravet syndromes.[1] There were able to 
appraise 1391 people who had taken CBD for epilepsy. The median exposure was 275 days 
and the maximum 1025. There have been twenty deaths reported – most appear to have 
been late, rather than early or immediately after receiving the drug. One was during the 
20mg/kg trial phase, seven in the open-label extension and 12 in the expanded access 
programme. There were no deaths with placebo. Although many of the deaths could be 
attributed to the progression of the underlying disease (mitochondrial disorder and Batten’s 
disease were mentioned), eight were either respiratory in nature or described as a SUDEP. 
This is important because CBD has a clinically relevant effect in potentiating clobazam. The 
FDA report considered the documented rise in serum transaminase as a clear drug effect – 
seen in 4% of cases but 0% placebo, although there were no cases of true hepatic failure. In 
a study of patients in the extended access programme 75% of those with significant 
increases in liver enzymes were co-prescribed valproate.[8] The FDA also drew reference to 
the infection rate – pneumonia in 4% of cases (0% placebo) and somnolence 2% of cases 
(0% placebo). The pneumonia risk was notably 9.1 times higher in those receiving CBD.  
Finally, there are open-label studies being published beyond Epidiolex. Tilray 2:100 is a 
mixed THC/CBD compound containing 2mg/mL THC and 100mg/mL CBD. In a study aiming 
to establish dosing and tolerability, 20 children with Dravet were trialled on this drug for 20 
weeks.[9] Even in such a small study there were reported significant improvements in 
quality of life, and a reduction in motor seizures of 71%, with a 50% responder rate of 63%. 
 
What do patients need to know? 
New medications are desperately needed as 30–40% of people with epilepsy do not 
respond to traditional medication regimens.[10] This is more likely when the person with 
epilepsy has additional needs such as autism and intellectual disability. There is a great deal 
of concern from patients and their families about the long-term effects of chronic 
antiepilepsy drug use. Much of this is well founded with drug-specific concerns such as 
retigabine causing blue-staining of skin and retinal pigment,[11] and drugs such as 
carbamazepine being associated with osteoporosis and accelerated atherosclerosis.[12] 
Others are concerns seen across most antiepilepsy drugs such as the neurodevelopmental 
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consequences of valproate exposure in utero (but also other antiepilepsy drugs at high 
doses or at polytherapy) or the generalised and cerebellar atrophy associated with chronic 
drug exposure.  
Not all drugs are designed; some are repurposed and some are serendipitous accidents. 
There is a desire for more ‘natural’ – and less ‘toxic’ medications. Unfortunately, there is a 
strong correlation in the public consciousness with plant-based medications and a 
supposition that these have milder side effects and make safer drugs. The pharmaceutical 
companies do nothing to dispel this misinformation by promoting their industrial agriculture 
plants. Aspirin is a wonder drug—and digoxin has undoubtedly helped millions—but both 
are characterised by the presence of their adverse side effects and drug interactions rather 
than the lack of them. Cyanide, of course, is a natural drug. That cannabidiol is derived from 
the street drug cannabis—and yet still patients equate the drug with safety—speaks to how 
cannabis use has broken into the mainstream of Western culture, and how safe many 
people must see this illegal substance. 
 
The desire for this to work 
We have a major issue with the placebo effect in clinical epilepsy and in epilepsy drug 
trials.[13] This is in part because we have no biomarker for seizure frequency or for epilepsy 
control. If only we had an HbA1c for epilepsy. The second factor is that for eligibility to enter 
a trial we often require patients to demonstrate a high seizure load in the weeks before the 
study starts. This may not be their habitual seizure frequency and, as a result, often doing 
nothing would allow their seizures to be become less frequent: the phenomenon of 
returning to the mean. We also risk this when changing medication at times of crisis. Too 
often patients talk about a drug having a ‘honeymoon’ effect – by which they mean, when a 
new drug was started it seemed to work – but then the seizures returned. Anecdotally 
however, we have been told of parents coming back to clinic and blaming themselves rather 
than CBD for its failure – so strong is their conviction that this drug will work for their child. 
The placebo response to the drug is high and the parents have been slow to report negative 
side effects. I have certainly had more patients speak to me openly about their chronic 
Cannabis and Epilepsy 
Page 8 
 
cannabis use recently – often with the expectation that I may suggest that it should 
continue for its medical benefits.  
 
Vulnerability 
Patients are remarkably vulnerable currently because cannabis products including artisanal 
cannabis oils – at variable concentrations - are available at high-street retailers such as 
Holland & Barrett, from independent retailers (so called head shops) and via on-line sources 
(Figure 2). Interestingly, some high street retailers stock the oil under ‘Homeopathic and 
Flower remedies’. We currently have no independent way to quantify for our patients what 
is in these substances. It is important to state that these are not pharmaceutical-grade 
products. Moreover, we cannot advise about sources, doses or regimens. A community-
based study of patients supplying their own CBD showed that doses reported by parents 
ranged from 0.5 to 28.6 mg/kg/day, and THC dosages ranged from 0 to 0.8 mg/kg/day.[14] If 
patients are frank with us that they are taking these supplements, then we may choose to 
monitor serum antiepilepsy drug concentrations for clinically relevant drug interactions. It is 
likely that all available CBD is subtherapeutic, but still problematic. CBD does not readily 
cross the blood–brain barrier and therefore it is possible to have peripheral effects and 
drug–drug interactions without the required central effects.  
Often these patients are on a clinical knife edge and are hospitalised with seizures from time 
to time. We cannot ask our nursing staff or pharmacists to handle these substances (literally 
or metaphorically) and therefore if patients were to continue them, then parents would 
need to administer every dose. Similarly, until legalised, tolerated or prescribable, patients 
on named-patient basis only schedules are at risk of a Home Office volte-face and the 
removal of their drug. There are political and economic groups that support the legalisation 
of cannabis who will seek to exploit individual cases for the greater benefit of their cause. 
There is no limit to what advocates have claimed medical cannabis can cure, but the failures 
are never publicised.(Figure 1) Medical cannabis has been cleverly marketed and has 
captured the imagination of much of the population.  
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Access to CBD 
The UK press reporting of epilepsy and cannabidiol shows much confusion. Artisanal CBD 
available on the high street is conflated with highly effective medications that have strong 
trial evidence. Little distinction is made between products with low THC content trialled in 
the UK, and CBD compounds where there is a greater than 0.2% THC content – which would 
be currently illegal in the UK. The situation is changing quickly and the Home Office has 
announced the creation of an Expert Panel that now has a published membership and terms 
of reference.[15] At time of writing, the process of application and access to prescriptions is 
opaque. Patients and clinicians alike are confused by headlines such as ‘Cannabis-based 
medicines get green light as UK eases rules’ (Figure 3) (Guardian 26th July 2018). 
 
What it would be nice to know 
How does CBD work? One would imagine that CBD would exert its effect via an interaction 
with cannabinoid receptors – but this is not thought to be the case and indeed we do not 
know the exact mechanism of the antiepileptic effect of CBD. We do know that CBD acts at 
multiple sites, which include intracellular targets such as mitochondria[16] and targets 
located on neuronal membranes—ion channels (voltage-gated sodium channels, voltage-
gated calcium channels), neurotransmitter receptors (GABA, 5-HT) and G-protein coupled 
receptors (GPR55). The ability of CBD to exert symptomatic benefits via multiple 
mechanisms may represent a novel poly-pharmacological approach to the disease. In a 
comprehensive review, Brodie et al.[17] made a compelling case for how CBD could exert a 
multitarget impact via: 1) inhibition of voltage-gated sodium channels; 2) activation and 
desensitisation of transient receptor potential cation (TRPV1) channels; 3) inhibition of 
rapamycin (mTOR) signalling; 4) direct modulation of 5-HT signalling; 5) indirect activation of 
adenosine and 6) the general inhibition of neuroinflammation. The CB1 receptor is where 
THC acts, whereas CB2 is the target for cannabinol. CBD has been hypothesised to have 
neuroprotective and anti-inflammatory effects; both of which would be attractive traits in 
an anti-epilepsy drug. This broad mode of action may well be a benefit rather than a curse – 
many of the most effective anti-epilepsy drugs, valproate for example, have diverse 
mechanisms of action.  
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What is the importance of serum THC concentrations in the cannabis-derived product for 
the control of seizures? There is no clinical evidence. Rosenberg et al.[18] reviewed the 
preclinical literature and reported that across 34 studies using six disparate animal species, 
THC demonstrated an anticonvulsant action (62%), proconvulsant (3%), mixed (3%) and no 
effect (32%) in seizure models. In the rodent maximal electroshock model of generalised 
seizures, THC was capable of increasing the effects of phenytoin and phenobarbital [19,20] . 
In addition to the CB1/CB2 receptor-related effects of THC upon neuronal excitability [18] 
and neurotransmitter release, THC is also likely to influence seizure activity via anti-
inflammatory [21] and anti-oxidant [22] actions. In addition, similar to CBD, there is 
evidence for THC’s ability transiently to activate and desensitise transient receptor potential 
(TRPA1, TRPV1 and TRPV2) channels.[23-25]. However, the consequences of high-dose THC 
on the juvenile and still-developing brain are currently unknown.  
Cannabidiol and clobazam have bi-directional and a clinically relevant drug interaction. This 
is because CBD inhibits cytochrome P450 (CYP)2C19 and increases serum concentrations of 
the clobazam metabolite, nordesmethyl. In the recently published data from the CBD 
extended-access programme 59% of patients reduced their baseline clobazam, 50% reduced 
their baseline valproate and 21% their levetiracetam. The rate of reported somnolence was 
2.7 times more likely in patients who were co-prescribed clobazam.[8] 
Does CBD produce most of its effect by potentiating the effects of clobazam – should there 
be a co-drug?  This theory may be supported by recent evidence which shows that CBD acts 
as a positive allosteric modulator at the GABAA receptor.[26] This finding raises the 
possibility that combined dosing of clobazam and CBD may produce a synergistic 
augmentation of GABAA receptors and enhanced seizure control. Demonstration of 
synergism requires use of specific methods of analysis that include isobologram analysis. 
Future well-designed preclinical studies using such approaches would be critical to support 
this hypothesis of synergy with, if positive, subsequent translation to rigorous clinical trials.  
You could ask, what would be the risks associated with immediately licensing CBD and 
cannabis-derived products for all people with epilepsy? We fear that the regulatory trials 
would not be completed. We would be less likely to have open reports from phase four 
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extension studies, but adverse effects would still be yellow-carded. This might be very much 
like our current situation with the ketogenic diet. We would not have guidance as to who 
best would respond to CBD. The ketogenic diet has crept slowly from paediatric to adults 
practice and is extending out now to neuro-oncological studies because drug companies are 
not bank-rolling further trials. We could be left with the strong trial evidence in Dravet and 
Lennox–Gastaut syndromes, but the evidence may not be well escalated beyond people 
with multiple seizure types that include myoclonic seizures. It would be a mistake to rush to 
license CBD and cannabis derivative products without completing the therapeutic licensing 
process. 
 
What do neurologists and need to know? 
1. We need to be better at identifying and diagnosing Lennox–Gastaut and Dravet 
syndromes. Dravet is common at an estimated incidence of 1 in 20,000 births.[27] 
We advise improving links with paediatric neurology, and having more enthusiasm 
for epilepsy gene panel testing and ‘medical archaeology’ (digging in to the old 
notes). 
2. CBD is not the only treatment for people with Dravet syndrome; stiripentol and 
fenfluramine are both effective and long term published clinical data confirm their 
safety profile and longer-term efficacy. [28,29] 
3. We need to be alert to new drug interactions: do we need to be testing serum 
concentrations of clobazam? 
4. People will be ‘taking matters in to their own hands’ and there may be an upswing in 
the recreational use of cannabis in an attempt to help their seizure control.  
5. There are many unanswered questions.  Are people who are seizure free but taking 
cannabis-derived medication safe to drive? How do we counsel women who may 
become pregnant?  
 
Summary 
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We are excited about the possibilities of this new agent, and excited that patients appear to 
want to trial this product. As medics, we should divorce our thoughts about artisanal 
cannabidiol oils from the cannabidiol rigorously tested in clinical trials. CBD is not a panacea, 
but nor is it our first step towards inevitable societal doom. The arguments about who may 
benefit from cannabis-derived medicines should be entirely uncoupled from discussion 
surrounding the legalisation of recreational cannabis 
 
Provenance and peer review.  Commissioned. Externally peer reviewed by Helen Cross, London, 
UK. 
 
Key Points 
We should divorce our thoughts about artisanal Cannabidiol oils from the Cannabidiol 
rigorously tested in clinical trials.  
Cannabidiol is not a panacea, but nor is it our first step towards inevitable societal doom. 
The arguments about who may benefit from cannabis-derived medicines should be entirely 
uncoupled from discussion surrounding the legalisation of recreational cannabis.  
Cannabidiol medications may not primarily work on cannabidiol receptors and may have 
significant interactions with clobazam 
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Figure 1: N=1 trials and the power of anecdote. Social media claims regarding CBD and 
cancer (12th July 2018). All claims regarding the treatment of cancer would likely contravene 
the Advertising Standards Agency requirements in the UK  
 
 
Figure 2. Artisanal CBD is sold as a dietary supplement.  A patient shows me their CBD oil 
bought on line and we have no way to assay the contents of the agent. 
 
 
Figure 3: CBD in the press. A new application process has been announced but families are 
very confused about the availability of medicinal-grade CBD. There needs to be rigorous 
regulatory and monitoring processes around this scheme. 
 
